Cancer Roundup: Biden Treatment, Vaccine Initiative, Tucatinib Approval
This cancer news roundup includes Hunter Biden's account that his father's metastatic prostate cancer treatment has been extremely difficult. It also covers a congressional candidate's acute myeloid leukemia diagnosis, the NIH's accelerated effort on therapeutic cancer vaccines, and multiple trial and regulatory updates. Among the regulatory news, the FDA expanded tucatinib's approval for first-line maintenance in metastatic HER2-positive breast cancer.
Hunter Biden described his father’s advanced prostate cancer, which has reached the bones, as extremely painful to treat. Separately, Virginia Republican congressional candidate Doug Ollivant disclosed an acute myeloid leukemia diagnosis. The NIH is pursuing a faster therapeutic cancer vaccine effort, largely using mRNA platforms.
In a phase III myeloma study, iberdomide plus daratumumab and dexamethasone improved MRD-negative complete response rates versus bortezomib in the first stage. A firmonertinib lung cancer trial missed its progression-free survival goal. The FDA broadened tucatinib’s use with trastuzumab and pertuzumab for initial maintenance in metastatic HER2-positive breast cancer.
These updates could affect patients with prostate, breast, blood, lung, bladder, and lymphatic cancers, along with their families and clinicians. A high-profile prostate cancer account may raise awareness of treatment burden, while the NIH vaccine effort may shape future research. The tucatinib expansion may widen maintenance options for some HER2-positive metastatic breast cancer patients. New sequencing and urine-test findings could improve detection, but CAR-T program cuts and limited exercise-program access may constrain some patients’ options.